CLOs on the Move

Acusphere, Inc.

www.acusphere.com

 
Acusphere, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Cambridge, MA. To find more information about Acusphere, Inc., please visit www.acusphere.com
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

MD Logic

MD Logic is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Guadalupe Valley Hospital Foundation

Guadalupe Regional Medical Center is committed to providing sophisticated facilities and services with an emphasis on personalized care.

Pines Of Sarasota

Pines Of Sarasota is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Finley Hospital

The Finley Hospital, a 142-bed facility, seeks to provide a continuum of care for all patients - newborn to geriatric.

MolecularMD

MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.